London, United Kingdom
Myricx Bio is an innovative UK-based biotech company, established in 2019, with a mission to revolutionize cancer treatment through their novel technology. The company's tagline, "Developing a new class of ADCs based on NMT inhibition to treat cancer," reflects its pioneering approach in creating selective cytotoxic payloads for antibody drug conjugates (ADCs).
Through the inhibition of N-myristoyltransferases (NMT), Myricx Bio is developing a completely new class of these ADCs, which aim to target and treat cancer more effectively. Their headquarters are in the United Kingdom, situating them amidst a robust healthcare and biotechnology ecosystem.
In a substantial leap forward, Myricx Bio recently secured a £90.00M Series A investment on 08 July 2024, backed by prominent investors such as Novo Holdings, Sofinnova Partners, Abingworth, British Patient Capital, Eli Lilly, Brandon Capital, and Cancer Research Horizons. This significant funding underscores investor confidence and provides a solid foundation for scaling their groundbreaking cancer therapies to market.
